Omalizumab better treatment option for managing chronic spontaneous urticaria during pregnancy

Key findings are:

• Twenty-nine pregnant patients were evaluated. There were two groups, A and B.
• In group A, 23 patients, constituting 79.31%, conceived during omalizumab therapy.
• In group B, six patients, constituting 20.69%, initiated omalizumab therapy during pregnancy.
• Among group A, 23 births and one miscarriage were reported.
• 15/23 patients discontinued Omalizumab after discovering the pregnancy state, while 8/23 patients were exposed to Omalizumab during the entire pregnancy period.
• In group B, Omalizumab was introduced at 10.83 ± 3.60 weeks of gestation. The patients in this group were exposed to it until the end of pregnancy. This group had seven live-born infants, including five singletons and one twin pair.
• No adverse events, complications or congenital anomalies were reported.

The objective of this retrospective study was to evaluate the efficacy and safety of Omalizumab in a cohort of 29 pregnant women who had severe chronic spontaneous urticaria and were resistant to second-generation H1-antihistamines.

They said Omalizumab for managing CSU before and during pregnancy does not negatively affect maternal and fetal outcomes.

Reference:

Cataldo Patruno et al. Safety of Omalizumab for chronic urticaria during pregnancy: a real-life study, Clinical and Experimental Dermatology, 2023; llad386.